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Tissue engineering has been considered as a third treatment modality complementing medicine and 
surgery. It was first defined in 1993 by Langer and Vacanti (1993). Today it is a rapidly growing 
field of research expanding to all disciplines in medicine. Currently, it is possible to engineer both 
hard and soft tissues in oral and maxillofacial surgery.  
Tissue engineering consists usually of three components: scaffolds, cells and regulating factors.  
Scaffolds are preferably biodegradable, i.e. they resorb when they are no longer needed while 
regenerated tissue fills the space of resorbed material. Different types of cells can be used 
depending on the type of required tissue. Both stem cells as well as differentiated cells have been 
used while regulating factors are most often growth factors. The growth of vascularization, to 
enable adequate delivery of nutrients and oxygen, must also be taken into account when constructs 
are of large size and diffusion is not enough to keep the construct vital. Regulating factors can be 
proteins, such as growth factors, culture media ingredients and structural or physical elements. The 
required tissue can be manufactured either in the body, on the site of the defect or ectopically, for 
example in muscular environment from where it is transplanted later, when mature enough, to the 
defect site. In this chapter, the past and the present of tissue engineering in oral and maxillofacial 


















Regenerative medicine aims at the functional restoration of tissue malfunction, damage or loss, and 
can be divided into three main approaches. Firstly, the cell-based therapies, where cells are 
administered to re-establish a tissue either directly or through paracrine functions. Secondly, the 
often referred to as classical tissue engineering, consisting of the combined use of cells and a bio-
degradable scaffold to form tissue. Thirdly, there are material-based approaches, which have made 
significant advances which rely on biodegradable materials, often functionalized with cellular 
functions (De Jong et al. 2014). 
 In 1993, Langer and Vacanti, determined tissue engineering as an “interdisciplinary field that 
applies the principles of engineering and the life sciences toward the development of biological 
substitutes that restore, maintain, or improve tissue function”. They published this definition in 
Science in 1993.  
Tissue engineering has been classically thought to consist of three elements: supporting scaffold, 
cells and regulating factors such as growth factors (Fig. 1). Depending on the tissue to be 
regenerated, all three vary. Currently, it is known, that many other factors may have an effect on the 
outcome of the regenerate. These include factors enabling angiogenesis, physical stimulation, 
culture media, gene delivery and methods to deliver patient specific implants (PSI) (Fig. 2). 
During the past two decades, major obstacles have been tackled and tissue engineering is currently 




Materials in tissue engineering can be manufactured with different techniques. The most common 
ones are molding and 3D printing. Scaffolds can also be porous granules inserted into a hollow 
container or biodegradable mesh, which provides the shape and size of the construct. The scaffold 
acts as extracellular matrix, which later is resorbed and replaced by proper extracellular matrix 
synthetized by cells. 
 




A large variety of materials have been introduced to aid tissue engineering both in soft and hard 
tissues. They can be used as scaffolds to keep the cells and growth factors in the desired area or 
only to give size and shape to the construct (a mesh filled with the scaffold material).  
In soft tissue engineering, collagen and freeze-dried cadaveric human dermis are currently most 
used material as scaffolds in oral and maxillofacial surgery (Kim et al 2017). They will resorb in 
due time leaving the cells to replace the missing tissue. In some applications, it is important to use a 
laminated scaffold to enable the growth of a 3D-structure with different tissue types.  
In bone tissue engineering, the most commonly used materials are biodegradable granules of beta-
tricalcium phosphate (ß-TCP), hydroxyapatite (HA) and bioactive glass (BAG) (Mesimäki et al 
2009, Dayashankar et al 2017, Stoor et al 2017a, Stoor et al 2017b, Kowal et al 2017). The mesh is 
usually made out of titanium or bioresorbable materials such as polylactic acid (PLA) or its 
composites. The scaffold materials as well as the bioresorbable mesh will degrade and the space is 
filled with newly formed bone. The speed of degradation depends on the used materials.   
The mesh is often shaped manually or with indirect printing, where a template of the defect (and 
required reconstruction) is manufactured and the mesh shaped to surround it. It can also be 
manufactured with the aid of direct 3D printing. 
 
3D printing 
With 3D printing, it is possible to produce custom made scaffolds and mesh for tissue engineering. 
By using of computer aided design and manufacturing (CAD-CAM), the scaffolds will be very 
precise and accurate. As facial structures are quite complex, this has brought huge advantages to 
managing different materials. Most used techniques are inkjet printing, laser-assisted printing, 
extrusion printing and stereolithography. All these require top-class imaging and manipulation the 
data as well as fine algorithms. CAD–CAM in medicine consists of four consecutive phases: (1) CT 
3D imaging data; (2) data conversion, CAD; (3) planning of surgery/manufacturing of implant; and 
(4) actual surgery accordingly (Seppänen-Kaijansinkko and Kontio 2017). After the scaffold has 





In tissue engineering, both differentiated primary cells as well as stem cells can be used as a source.  
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Primary cells are cells taken from living tissue. They have undergone only a few divisions and, 
hence, represent the cells in the original tissue extremely well. The main obstacle when using these 
cells is the limited number that can be obtained. 
 
Stem cells 
Stem cells are cells which can make perfect copies of themselves (self-renewal) or differentiate to 
specialized cell types. Several cell types are gathered under the same umbrella called ‘stem cells; 1) 
human embryonic stem cells (hESCs), 2) human induced pluripotent stem cells (hiPSCs), which are 
in fact reprogrammed somatic cells, and 3) adult stem cells, which cover several types of cells of 
hematopoietic and mesenchymal origin. Mesenchymal stem cells (MSCs) and tissue-specific 
progenitors reside in the human body in most tissues throughout an individual’s life and generally 
have a limited expansion and differentiation.  
Pluripotent stem cells can differentiate to all specialized cell types. The main source is the inner cell 
mass of human embryo (hESC) but lately hiPSCs have gained a lot of interest in clinical cell 
therapy and regenerative medicine (Fig 3). When making iPSC lines, somatic cells are genetically 
reprogrammed using transcription factors (Takahashi et al. 2007, Yu et al. 2007). When using both 
hESCs and hiPSCs there is a risk of mutations already in the laboratory, due to the lengthy in vitro 
culturing time and extensive cell manipulation (International Stem Cell Initiative 2011). In vivo 
reports of tumorigenicity have raised concern for safe in using these cells in clinical work 
(Csobonyeiova et al. 2015).  
Some of the most promising research in regenerative medicine is focusing on the use and 
applicability of stem cells. The main stem cells used in tissue engineering are tissue derived, so 
called adult stem cells, which can be extracted from most adult tissues. They can be transplanted 
back to the same individual (autologous transplantation) avoiding risks of disease transfer or 
immunological reactions. They can also be transplanted to another individual (allogenic 
transplantation) (Rosenbaum et al. 2008). 
Mesenchymal stem cells (MSCs) are of great interest to both clinicians and researchers, due to their 
great potential in tissue engineering. Their ease of isolation and manipulation, and potential for 
differentiation are qualities that have gathered interest. Despite their frequent use in research, 
detailed standardized criteria are called for as to the identification of these cells from their various 
locations, as they are not all the same; the International Society for Cellular Therapy has published 
a set of guidelines attempting to standardize the expansion of these cells but more standardization is 
still needed (Horwitz et al. 2005, Dominici et al. 2006, Krampera et al. 2013). 
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The most commonly studied MSCs are derived from bone marrow (bone marrow stem/stromal 
cells; BM-MSC) and adipose tissue (adipose tissue stem/stromal cells; AT-MSCs). While both BM-
MSCs and AT-MSCs have an approximately equal potential to differentiate into cells and tissues of 
mesodermal origins (i.e., adipocytes, cartilage), AT-MSCs have a distinct advantage: they are more 
readily accessible than BM-MSCs. While comparative analysis of the two subtypes of MSCs has 
shown that there is no difference in regard to morphology, immune phenotype, isolation success 
and colony frequency, differences do arise in regard to osteogenic and chondrogenic differentiation, 
with AT-MSCs exhibiting smaller potential for osteogenesis and chondrogenesis than BM-MSCs 
(Rosenbaum et al. 2008) (Figs 4 and 5). 
MSCs are currently the focus of clinical and scientific research due to their exceptional abilities for 
their immunomodulatory properties. However, MSCs cannot be considered truly 
hypoimmunogenic; rejection of allogeneic MSC immunosuppressive potential and immunogenicity 
are influenced by levels of systemic or local inflammatory cytokines. High immunosuppressive 
potential simply allows MSCs to suppress inflammation and delay allogeneic rejection through 
suppression more efficiently than other allogeneic cell types. Many believe that the therapeutic 
effect of MSCs is due to a ‘hit-and-run’ mechanism mediated by the production of extracellular 
vesicles (EVs) or exosomes or secretion of trophic and immunomodulatory factors. Nevertheless, a 
comprehensive understanding of MSC mechanism of action in cell therapy is still under 
investigation and many questions remain to be answered (Ankrum et al. 2014). 
Adult stem cell-based therapies are already clinically available, additionally, more than 3,000 trials 
associated with stem cells are currently registered in the World Health Organization International 
Clinical Trials Registry Platform (http://apps.who.int/trialsearch/). The majority of these are adult 
stem cell-based therapies, but the registry also includes the first pluripotent-based (hESC/hiPSC) 
clinical trials, associated with eye diseases such as macular dystrophy or degeneration. Albeit that 
the technology is in place to produce a wider range of therapies, especially safety issues are not 
completely understood, subsequently there is a cautious transition from bench to bedside and 
application of technologies. (Ankrum et al. 2014) 
 
Bioprinting 
The cells can also be printed together with certain biomaterials combined with growth factors, if 
needed. The first bioprinting technique was inkjet printing, which is fast and cost-effective. The 
resolution is high but the quality of vertical structure is poor. Cell density is also low. It has been 
used to engineer blood vessels, bone, cartilage and neurons. (Tuan et al. 2003) 
   
 
 7 
When using laser-assisted printing, the cost is high while cell viability is excellent (>95%). The 
resolution is high and the vertical structure quality is fair. This technique has been used in blood 
vessel, bone, skink and fat regeneration. The high cost has prevented this technique becoming very 
common. The printers are mostly complex and cumbersome compared to other types of printers. All 
in all, this technique is still immature for clinical work. (Mandrucky et al. 2017, Keriquel et al. 
2017) 
Stereolithography is also relatively cheap and fast. The resolution is high and the quality of vertical 
structure is good with good cell density and cell viability (>85%). It has been used in blood vessel 
and cartilage engineering. (Gou et al 2014, Mandrucky et al. 2015) 
Bioprinting by extrusion, which is modified inkjet printing, can be used when biomaterial is very 
viscous.  It is of moderate cost but slow. Cell viability is also moderate (40-80%), resolution 
moderate but vertical structure is of good quality with high cell density. Currently, most commonly 




Bone morphogenetic factors (BMPs) play a central role in bone and cartilage development, as well 
as in adult homeostasis of bone metabolism, but also ow known to play crucial roles in all organ 
systems. Therefore, it has even been suggested that BMPs should be named body morphogenetic 
proteins (Reddi 2005). Currently, the BMP family is comprised of several members from BMP-2 to 
BMP-18.  
Though BMPs were initially discovered to induce bone formation, BMP-3 for instance has been 
shown to be a negative regulator of bone density. Some BMPs may have redundant roles in bone 
formation, as conditional deletion of BMP-7 from limb has no noticeable effect (Wang et al 2014). 
Further, the osteogenic potential of BMPs have reported contradictory results in in vitro studies. In 
two- and three-dimensional cultures of AT-MSCs, supplementation of BMP-6, BMP-7 and vascular 
endothelial growth factor (VEGF) and their combinations showed no significant enhancement of 
the osteogenic differentiation (Kyllönen et al. 2013), while others reported a synergistic effect of 
BMP-6 and VEGF on the osteogenic differentiation of the same cells (Li et al. 2015). In a study 
using periodontal ligament cells, supplementation with BMP-2 or BMP-6 showed no enhanced 
osteogenesis (Khanna-Jain et al. 2011) 
BMP-2 is best studied in the context of osteogenesis and has been indicated to have potential in 
bone formation, however, the reports have been contradictory both in vitro and in vivo. 
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Nevertheless, studies suggest that source of serum supplementation of the in vitro cultures may play 
a role, with human serum supplemented media showing accelerated biochemical responsiveness to 
BMP-2 compared with fetal bovine serum (FBS) in AT-MSC cultures (Vanhatupa et al. 2015). 
Further, the species origin in which the growth factor is produced is of the also important for its 
response, with BMP-2 of mammalian origin showing enhanced response in vitro compared with 
BMP-2 of bacterial origin (Vanhatupa et al. 2015). These results may give one explanation to the 
existing contradiction in the reported BMP- 2 studies on AT-MSCs in vitro. 
Due to their approval for clinical use, BMP-2 and -7 are probably the most studied growth factors 
for bone tissue engineering. However, the translation of BMP-2 and -7 to clinical use has been 
hindered by various problems, including high administration dosage, safety issues, short half-life 
and high cost relative to efficacy (Garrison et al. 2007). The safe administration dosage may be one 
the reason to the complications and safety issues concerning BMP-2 in off-label use in the cervical 
spine to increase bone growth and bony fusion. The FDA published a safety communication on 
recombinant human BMP-2 use in 2015, especially for pediatric patients, with recommendation to 
cautiousness in the use of BMPs until further safety evidence is available.  
 
Enhancing osteogenesis using physical stimulation 
 
Bone is a tissue capable of modifying its structure and mass according to the mechanical loading it 
is exposed to. This process occurs through the intrinsic balance in the mechanosensitive activation 
of the osteoblasts and the osteoclasts (Palomares et al. 2009). 
Several of studies have provided robust evidence that reduced mechanical loading results in 
decreased bone mass, and that increased mechanical loading can be utilized to enhance bone 
formation in vivo as well as in clinical cases. Further, animal and human studies have led to the 
examination of mechanical loading in cell models. Studies have shown, that bone cells and their 
pre-cursors and also MSCs exhibit mechanosensitivity in vitro in response to various mechanical 
stimuli, however, there is no consensus on the most effective combination of vibration loading 
parameters for osteoinduction (Kyllönen et al. 2011).  
Further, osteogenesis can be enhanced in vitro using another potential strategy, by application of 
conductive polymers as a functional surface coating on biomaterial scaffolds. One of the conductive 
polymers (CPs), polypyrrole (PPy), has shown great promise in tissue engineering, not only because 
it can mediate electrical currents, but also because it may enhance the bioactivity of biomaterials in 
bone applications. Reports show, that AT-MSCs cultured on polymer scaffolds coated with PPy 
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induced with electric stimulation supported the viability and proliferation of the AT-MSCs as well 




In preclinical studies, regeneration of many tissues in the oral and maxillofacial have been studied. 
Of these, teeth, salivary glands and nerves have not yet been explored in clinical applications. 
 
Teeth 
Considering teeth, many different types of cells are needed, including dental pulp regeneration, 
dentino- and amelogenesis (Dissanayka and Chang 2017, Wang et al. 2017, Hu et al. 2017).  In the 
future, it might be possible to regenerate the root of a tooth, but at the moment it seems impossible 
to guide the shape and color of the crown of a tooth. Hence, dental regeneration at least at the 
moments, cannot replace dental implants. 
 
Periodontal ligament  
Infection leading to loss of periodontal ligament is very common in adults and the treatment 
methods need improving (Hu et al. 2017). In long term cultures, surprisingly, estrogen seems to 
have properties to retain the stemness of periodontal ligament stem cells (Ou et al., in press). New 
materials such as zein (protein derived from corn) can be electrospun with gelatin and seems to 




Salivary gland regeneration has been studied quite extensively, however, no clinical studies have 
been reported yet. Salivary hypofunction can be caused by systemic diseases such as Sjögren's 
syndrome, but it may also be due to radiotherapy in the head and neck region. Secretion of saliva is 
extremely important for the well-being of oral mucosa and teeth, however, no adequate saliva 
substitutes to replace the hypofunction of the glands has been developed. For tissue-engineered 
salivary gland, it is necessary also to be able to connect the secretion of saliva to the complex ductal 
system to deliver the saliva to oral cavity. However, function of salivary glands including secretion 
of bioactive molecules in case of radiotherapy might be feasible when using AT-MSCs 
administrated by systemic routes, i.e. blood stream, by paracrine mechanisms which will provide 
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growth factors helping neovascularization and promoting epithelial proliferation as well as 
angiogenesis (Tabatabaei and Sheykhhasan 2017). Dental follicle –derived stem cells have been 
shown to be able to differentiate to salivary gland and duct cells, which might be a promising future 
treatment modality (Xu et al. 2017).  
 
Cartilage  
In cartilage tissue engineering, committed chondrocytes, ESCs and MSCs have been used. Based on 
the results and availability of cells, MSCs seem to be a viable choice for this application. The 
regenerated cartilage in the joint will have to bear large contact area strains and stresses. It must 
also allow growth of functional tissue by providing appropriate cell-scaffold interactions (Seo and 
Na 2011). 
To enable long term survival of cells inside the scaffold, the scaffold must be either porous or 
woven. These properties will challenge the appropriate strength of the scaffold. In oral and 
maxillofacial surgery, the need for cartilage is usually in the temporomandibular joint (TMJ). 
Mäenpää with her coworkers (2010) studied the regeneration of TMJ discs in rabbits. The bilayer 
scaffold disc comprised of a non-woven mat of resorbable PLA and a PLA membrane plate. AT-
MSCs were seeded in the discs and cultured in parallel in control and chondrogenic medium for six 
weeks. Relative expression of the genes, aggrecan, type I collagen and type II collagen, normally 
present in the TMJ disc extracellular matrix, increased in the discs in the chondrogenic medium. 
They concluded that the PLA discs seeded with AT-MSCs have potential in the development of a 
tissue-engineered TMJ disc. The same group later used these discs in in ten rabbit TMJs. The 
original TMJ disc was bilaterally removed and the AT-MSC-seeded PLA disc was used to replace 
the removed original disc on one side. On the other side the cell-seeded PLA disc was pretreated in 
chondrogenic differentiation media. Unfortunately, the cone beam computed tomography and 
histology showed, that most of the discs had dislocated and caused sclerotic changes and condylar 
hypertrophy in the joints. The pretreated discs seemed to function slightly better than the non-
pretreated discs.  No signs of foreign body reaction, infection or inflammation could be seen. The 
authors conclude that better disc design and fixation technique might lead to better results 
(Ahtiainen et al. 2013).  
To be able to regenerate mandibular condyle, it must be realized that both the bone and the cartilage 
must be produced and bound together. Chondrocytes and osteoblasts can be harvested or 
differentiated from above mentioned many sources: The properties of the scaffold needed is 
different for bone and for cartilage. The growth factors used need to differ as well. However, if this 
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could be safely and predictably performed, this approach would give great relief to patients 
suffering from major TMJ disorders and diseases. (Wang and Detamore 2007)  
Nasal cartilage has also been a target for tissue engineering. Chang et al. (2007) used autologous 
chondrocytes injected in fibrin glue to rabbits´ dorsal nasal bones. The histological result was 
identical to that of normal auricular cartilage. The concentration of fibrinogen and thrombin as well 
as chondrocytes play a crucial role in the formation of the cartilage. If cartilage cells are not 
available, bone marrow as well as umbilical cord derived stem cells have been studied. The 
umbilical cord derived cells seemed to produce more type I collagen and aggregan compared to 
bone marrow derived cells, a finding which warrants further studies also in a sandwich-type 




There are two main objectives in maxillofacial reconstruction:  surgery should provide form and 
function of oromaxillofacial area. As facial skeleton has a very complex structure, and 
reconstruction should restore volume, shape, bone continuity and symmetry of bone skeleton. On 
the other hand, soft and hard tissues in this area enable several functions like articulation, mimics, 
mastication, swallowing and breathing. When the reconstruction is carried out, esthetic and 
reconstructive aims need to be met. 
Clinically, the applications have been mainly in bone regeneration as well as in epithelial defect 
repair. Currently, the aim is also to avoid all animal-derived materials and replace them with 
synthetic or human-derived materials, such as recombinant human BMP (rhBMP) and human 
serum. 
 
Soft tissue regeneration 
Currently, surgeons often use collagen sponges and freeze-dried cadaveric human dermis to replace 
missing soft tissue (Kim et al. 2017). However, tissue-engineered approaches have also been 
introduced and they will be elucidated below. 
 
Oral Mucosa 
Oral mucosal grafts have also been used in clinical work. EVPOME®, a tissue engineered ex vivo-
produced full thickness mucosal graft, has shown the ability to create keratinized mucosal surface 
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epithelium when grafted on an intact periosteal bed. EVPOME® is manufactured in the laboratory 
from the patient's own keratinocytes (from biopsies of the palate) seeded and cultured on an 
acellular dermal matrix.  It has proven to be safe and have potential to augment keratinized mucosa 
around teeth. (Izumi et al. 2013) 
 
Lips  
On top of esthetics, lips provide several other functions. These include eating (closure of the oral 
cavity), breathing (by nose), articulation and sensation (hot, cold, etc.). They also play an important 
role in facial expressions. 
Regeneration of lips is very difficult especially when there is a large defect which cannot be 
repaired with local flaps. To regenerate an avulsed lip, both the surface structures (underlying 
muscles and surface structures such as skin and mucosa) have to be considered. (Duisit et al. 2017) 
For tissue-engineered construct to be successful, it needs adequate blood supply to enable survival 




Already approximately one million patients, mainly burn patients and patients with diabetic ulcers, 
have received tissue engineered human skin. Dermagraft® (PGA + neonatal fibroblasts) was one of 
the first commercially available products for skin defects (Langer & Vacanti 2016). Currently, 
allogenic skin grafts are available as off-the-shelf products. However, they are somewhat 
immunogenic and may transfer diseases, although the risk is minimal after extensive testing 
required for these products. Skin grafts can be manufactured to replace only epidermis or dermis of 
both. Unfortunately, hair follicles or sweat glands are not yet included in these grafts. 
 
Hard tissue regeneration 
 
Cartilage 
Our own research group has used tissue engineering to produce cartilage to the nasal septum. The 
two operations, in which a resorbable Chronos® sheet was seeded with patients' own ASCs, were 
successful. However, one of the patients continued her nose picking with artificial nails and after 
the initial healing period the graft was lost. (Sandor et al. 2014).   
 




Bone transplants are the second most used tissues in clinical work after blood transfusions (Shegarfi 
and Reikeras 2009). However, if autologous bone is used, usually another surgical site required 
which causes more morbidity to the patient as well as extends the length of the operation. Bone 
banks provide solution for this is some cases as allogeneic bone can quite safely be used even 
though there is a small risk of immunologic reactions and disease transfer. Bone grafts usually 
resorb partly, hence, in oral and maxillofacial area it might in some cases be difficult to predict how 
much bone needs to be transplanted.   
 
Sinus lift 
Sinus lift is one of the most common procedures to enable placement of dental implants in the 
edentulous maxilla. Traditionally it is carried out by using autologous bone harvested in the 
craniomaxillofacial skeleton or iliac crest. However, it was one of the first application where bone 
regeneration was attempted by tissue engineering. The used carries for cells and/or growth factors 
are resorbable fleeces, HA, bovine bone and, naturally, autologous and allogenic bone.  
Schimming & Schmeltzheisen (2004) used periosteal cells on a resorbable (polyglactin 910 
combined with polydioxanone) fleece in 27 patients for augmentation of edentulous posterior 
maxilla. They used Good Manufacturing Practice (GMP) -class expanded periosteal cells from 
mandibular angle and the fleece was soaked with cell suspension. Bovine thrombin in FBS was 
used to seal the cells in the fleece. Cells were cultured for nearly 2 months after which they were 
transplanted in the sinus floor. One patient had to be dropped out due to an infection. In 18 patients 
the result was excellent, however an unsuccessful result was seen in 8 patients (30%) needing 
further supplementary autologous bone transplantation. 
Meijer et al. (2008) augmented sinus floors or walls prior to dental implant insertion in six patients. 
BM-MSCc were harvested from iliac crest and cultured for a week on porous HA in an osteogenic 
culture medium, containing also xenogeneic materials such as FBS. The cells were then 
transplanted and the augmentation effect studied 4 months after augmentation. Of the 11 biopsies 
taken, bone formation was observed only in 3 patients (50%). It can be speculated, that inadequate 
vascular supply might have been the reason for failures. 
 
Other small local defects 
In oral and maxillofacial surgery, large bone defects, caused by cysts, are often filled with 
autologous bone, bovine bone or synthetic materials such as hydroxyapatite (HA), ß-TCP or BAG. 
In a study published by Stoor et al. (2017a) 21 bony cavities in 20 patients were filled with BAG 
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S53P4, some even in the presence of infection (65%). The authors state that the use of this material 
provides and infection-free and reliable bone regeneration. When cells have been used, autogenous 
osteoblasts seeded in biomaterials have shown to be an excellent choice to fill these defects 
compared to iliac crest bone grafts (Pradel et al. 2006). Unfortunately, the need for a GMP-class 
facility to produce the tissue engineered filling materials is very labor-intensive and not very cost 
effective hindering their use to become more widespread. According to current legislation, iliac 
crest bone graft can be obtained simultaneously during the same operation when the cyst is 
removed, hence lowering the costs markedly. 
 
Continuity defects 
Continuity defects are caused mainly due to tumor ablation of trauma. The can include only the 
bone, sometimes teeth and some soft tissue. If the soft tissue coverage and blood supply to it is 
adequate, it is possible to tissue-engineer the transplant directly in the defect site. However, if there 
is a major loss of soft tissue, the construct needs to be transplanted first to an ectopic site and after 
maturation transplanted again to the defect site either as a microvascular flap or a pedicled flap. 
 
On-site regeneration 
Zétola and his coworkers published a case report in 2010 of a repair of a mandibular defect repair 
after resection of an ameloblastoma using recombinant human morphogenetic protein-2 associated 
with collagen sponge, autogenous bone chips and synthetic HA and β-TCP blocks. No cells were 
transplanted. Titanium reconstruction plate and titanium scaffold filled the above-mentioned 
combination was implanted into defect area. Collagen with rhBMP-2 was superposed above open 
titanium mesh to allow muscle cells and periosteum to migrate to defect area. After 7 months, the 
patient had a stable occlusion. Control CT showed good bone formation directed to the center of the 
defect. The authors concluded that the reported reconstruction technique gave a satisfactory result 
with less invasive surgery and with minimum morbidity. However, studies with larger number of 
patients are required to indicate the treatment modality as a routine in cases of bone continuity 
defects. 
In 2015, Park et al. reported a case study, where a large continuity defect after resection of 
ameloblastoma in the angle of the mandible was reconstructed with iliac bone and autologous BM-
MSCs. The iliac bone served as a scaffold, fixed with titanium plates and screws, with cancellous 
bone removed. The gap was then filled with cultured BM-MSCs and fibrin glue covered with 
collagen membranes. Later three dental implants were placed in the graft resulting in uneventful 
healing.  
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Stoor et al. (2017b) used direct CAD – CAM technique and tissue engineering to repair mandibular 
defects in 14 patients immediately at the time of ablation surgery. Most of the patients had 
squamous cell carcinoma or ameloblastoma. The surgery was simulated and patient specific implant 
(PSI) designed on virtual model. The PSI was a combination of scaffold and reconstruction plate 
with screw holes. The scaffold was filled with β-TCP and autologous bone.  In four patients with 
ameloblastoma or drug induced osteonecrosis cases BMP-2 soaked in a sponge was placed to cover 
the cage to improve the bone formation. Finally, PSI was covered with collagen membrane or 
sponge (10 patients) and either radial for arm or anterolateral thigh (ALT) microvascular flap (12 
patients). The follow up was between 9 – 24 months. The overall recovery of the patients was 
favorable considering how demanding the patients were. Nine patients had an uneventful recovery. 
The main reasons for failure were infection and dehiscence of the mucosa or the microvascular flap. 
In these cases, extreme caution should be exercised to avoid soft tissue injury or dehiscence during 
the surgery and follow up. 
It is noteworthy, that all these reports can be estimated having been successful due to sufficient 




One of the first clinical papers was published by Warnke and coworkers in 2004. They 
reconstructed a mandibular continuity defect using vascularized custom-made bone flap with 
indirect technique in which patient’s CT data was uploaded to CAD software and the defect 
reconstructed in the mandible was virtually simulated. A virtual implant to repair the defect was 
designed and converted into solid 3D Teflon replica, which was used as a model when manually 
shaping titanium mesh around it. The shaped mesh was filled with bovine bone mineral blocks 
combined with growth factor rhBMP-7, bovine collagen type-1 and autologous iliac crest bone 
marrow. The filled mesh was implanted into patient’s back muscle (latissimus dorsi). A 
microvascular flap was raised 7 weeks later and 4 weeks after the implantation the patient was able 
to use her mandible and was satisfied with the aesthetic outcome. The authors concluded that 
ectopic bone formation is possible and causes less burden to the patient compared to conventional 
bone grafts.  
Mesimäki et al. (2009) reconstructed a major hemimaxillary bone and soft tissue defect caused by 
removal of recurrent keratocyst in a middle-aged male patient. The patient was very unhappy with 
his removable obturator prosthesis. The construct consisted of ß-TCP as scaffold material seeded 
with patient’s autologous adipose-derived stem cells expanded in a GMP-class laboratory and 
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commercially available growth factor BMP-2. The material was the inserted into a titanium mesh 
preformed to fit the size and shape of the defect. The construct was first implanted into the patient’s 
rectus abdominis muscle, where it was let to mature for 8 months. After maturation, the construct 
together with the surrounding muscle was transplanted using microvascular technique (TRAM-flap) 
to the site of the defect and connected with titanium plates and screws to the adjacent bones. The 
anastomosis of flap recipient vessels was performed to neck vessels and flap was fixated with 
titanium plates. After uneventful healing, four dental implants were inserted into the regenerated 
bone and a fixed bridge was used to reconstruct the masticatory function. The histology obtained at 
the time of fixture operation confirmed normal bone tissue in heterotopic bone area. The follow-up 
has been uneventful for a decade, only some small pieces of titanium mesh have had to be removed 
as they have protruded through the thin oral mucosa (unpublished results). (Figs. 6-8) 
The same group performed similar reconstruction to a male patient after total maxillary defect 
caused by ablation of a large squamous cell carcinoma (SCC). The combination of AT-MSCs, β-
TCP granules, rhBMP-2 in polylactide scaffold was implanted into the ALT-flap and shaping of a 
resorbable polylactic scaffold was done with computer aided design, with indirect technique. 
Patient specific (PS) titanium reconstruction plates were used to fix the future ‘neomaxilla’. After 
maturation of 7 months the microvascular ALT flap with heterotopic bone was raised and placed 
into area of resected maxilla. Dental implants were inserted after uneventful healing of 5 months. 
The prosthetic reconstruction was established with removable prosthesis (unpublished results). 
The largest number of patients with using autologous stem cells in 13 consecutive cases of cranio-
maxillofacial hard-tissue reconstruction has been published by Sandor et al. (2014). The 
reconstruction was carried out with expanded autologous hAT-MSCs, β-TCP and in most cases, 
BMP-2.  The group reported on reconstruction of defects at four anatomically different sites: cranial 
bone (5), frontal sinus (3), mandible (3), and nasal septum (2). In the mandible, continuity defect 
repair was carried out using computer aided surgical planning and AT-MSCs. If scaffolds were 
needed, titanium mesh or β-TCP sheet was used.  The patients were followed between up to 51 
months. Two patients with mandibular reconstruction received a total number of seven dental 
implants later, which are being loaded in masticatory function. The authors concluded that although 
results are promising, further research is needed with animal studies and long-term human series. 
This view is supported by other research groups, too. 
Matsuo et al. (2010) used indirect technique in mandible defect repair.  After surgical simulation, a 
PLA PS mesh tray was manually prepared and filled with HA. Intraoperatively, particulate 
cancellous bone and marrow was harvested and with platelet-rich plasma (PRP) placed into the tray. 
Two patients with mandible defect was included to the study. The follow-up was 28 and 33 months. 
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One of the patients received dental implants after 10 months of the initial surgery. The heterotopic 
bone was macroscopically well formed. The CT evaluation showed good bone quality and the 
screws used to attach the resorbable mesh tray did not hinder placement of dental implants.  
The neovascularization with prompt recovery of nutrition is considered to be a key issue of bone 
regeneration.  Kokemueller and coworkers (2010) reported a clinical case of hemimandibular defect 
that was reconstructed with the combination of autologous iliac crest bone marrow, β-TCP and 
rhBMP-2 in titanium scaffold. The reason for the defect was chronic osteomyelitis. The patient 
suffered from several other comorbidities as well. They designed and produced β-TCP cylinder that 
had central passage with the diameter of 7mm. The for blood-soaked cylinders were implanted into 
latissimus dorsi muscle. Perforator vessels were placed into central passage to enhance capillary 
growth. After 6 months, the flap with heterotopic bone was raised and transferred to oral and 
maxillofacial (OMF) defect and covered with titanium mesh. The mesh was fixed with titanium 
screws. There was no complication during the follow up of 1 year. The authors conclude that the 
use of autologous bone marrow and β-TCP block with central vessels to repair OMF bone defects is 
reliable and well tolerated. Furthermore, most of the donor site morbidity can be avoided with this 
technique. The research group performed also experimental studies with same protocol and the 




Tissue engineering and regenerative medicine is regulated by FDA in US and by EMA in Europe. 
The manipulated cells are considered as Advanced Therapy Medicinal Products (ATMP) and the 
regulation is very strict. The engineered tissues must be manufactured according to Current Good 
Manufacturing Practices (cGMP) standards, which includes a flawless quality control system 
including testing of raw materials, establishing a detailed standard operating procedures (SOPs), 
detecting any deviations of these procedures, detecting possible contaminations as well as 
maintaining reliable testing laboratories and follow-up systems.  
 
Products available in EU 
 
In Europe, only four products have received manufacturing license, namely Chrondrocelect®, 
Zalmoxis®, MACI® and the only one using stem cells: Holoclar®. Of these, only two are available 
in the market at the moment. 
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Chrondrocelect® is a product where patient’s own cartilage samples are surgically removed from 
“less important” parts of the cartilage and the extracted chondrocytes are expanded in a GMP-class 
lab. The expanded cells are the inserted surgically to the defect site. For unknown reason, the 
marketing authorization for Chondrocelect has been withdrawn at the request of the marketing-
authorization holder in 2017.  
MACI® is quite similar to Chrondrocelect®, i.e. using patient's own chondrocytes expanded and 
seeded in a collagen matrix, which is transplanted to the defect site. At the moment, it is not 
available as the manufacturing site has not received an approval from EMA. If a new manufacturing 
site will be approved, MACI® could be available to the patients. 
Zalmoxis® is used for patients as an add-on treatment in adults who have received a hematopoietic 
stem cell transplant due to leukemia or lymphoma from a partially matched donor. Before receiving 
the transplant, the patient's own cells from bone marrow have been removed, hence, predisposing 
the patient to infections. Zalmoxis® contains genetically altered T-cells which will help the patient 
in restoring his/her immune system. Zalmoxis® is an orphan medicine and has been granted 
manufacturing license in 2016. 
Holoclar® is the first and only stem cell based ATMP product to enter the European market and 
received the manufacturing license at the end of 2014. It is aimed to help patients with a moderate 
or severe limbal cell deficiency in the eye, which can eventually cause blindness. Holoclar® is 
based on patients own limbal stem cells.  
 
Products manufactured in the operating room  
 
On the other hand, surgeons may combine cells, growth factors and materials in the operating room 
without any ATMP approvals as long as everything occurs during the same surgical procedure and 
the cells are used for homologous (i.e. same tissue type) reconstruction. The main obstacle causing 
high prices is the labor-intensive work carried out in GMP-class laboratories as well as the 




In order for tissue engineering and regenerative medicine to be feasible treatment methods, more 
detailed experimental studies as well as controlled clinical studies are needed. The manufacturing of 
these products is very expensive and often the end products are patient specific, preventing large 
scale manufacturing which could lead to cost-effectiveness. 
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It is still unclear, whether cells or growth factors are needed if local neighboring cells can initiate 
healing or growth factors are abundant in the area. This might be the case with bone defect and 
locally preserved periosteum. 
Growth factors and stem cells have been speculated to be a risk for malignant transformation. With 
mesenchymal stem cells this has not been proven. When using growth factors there still is a 
suspicion of hypertrophic growth and malignant transformation (O'Neill et al. 2016, Weiss 2015). 
Hence, they should not be used in patients with malignancies.   
Currently there is a shift occurring in the field of regenerative medicine, with less of the focus on 
cell-based treatment options and more weight is put on strategies that allow functional restoration of 
damaged tissues by cell-free approaches. Recent insights suggest that the structural contribution of 
stem cells to regenerated tissues is limited, and that it is rather the stimulation of local healing 
processes plays an important role, research has increasingly focused on the paracrine hypothesis, 
exploring the factors released by the cells, including growth factors, cytokines, and EVs (for a 
review, see De Jong et al. 2014).  
EVs are lipid membrane vesicles, containing a variety of RNA species, proteins, and potentially 
even DNA. EVs function in many processes, including cell-to-cell communication, immune 
modulation, angiogenesis, and cellular proliferation and differentiation. Cells release several types 
of vesicles with different physiological properties, and function (De Jong et al. 2014). Generally, 
the term EV is used when discussing exosomes or microvesicles, or a combination of these vesicle 
populations albeit conflicting definitions still exist (Gould et al. 2013). Extracellular vesicles are 
able to affect several cell processes in a paracrine manner. These paracrine effects of EVs have a 
potential benefit in regenerative medicine, as EVs can be incorporated in treatments for example by 
injection, mixing with hydrogels, or coating scaffolds with EV using fibrin gels or specific linkers. 
Subsequently, EV show great potential for a role in regenerative medicine. Given the supportive 
role of EV in tissue regeneration, further studies may lead to the discovery of novel regenerative 
therapeutics, as well as methods to improve current techniques. 
Despite of all regulatory and other hurdles, every year more clinical trials end up successful and 
eventually will lead to clinical applications. Multidisciplinary collaboration plays a key role in this 
process – we need clinicians, scientists, engineers, regulatory experts and many more specialists to 
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LEGENDS FOR FIGURES 
 
Fig 1. The classical triad of tissue engineering: cells, supporting scaffold and growth factors. 
 
Fig 2. Current concept of tissue engineering. The cells communicate with its environment with 
structural, physical, chemical and cellular components which brings complexity to tissue 
engineering. EVs are new area of interest, with potential applicability in stem cell therapy and tissue 
engineering. Image from https://www.esciencecentral.org/ebooks/ebookchapter/resident-stem-cells-
stimulation-new-promise-for-tissue-regeneration--165/3. 
 
Fig 3. Stem cell hierarchy. Zygote and early cell division stages to the morula stage are defined as 
totipotent. At the blastocyst stage, only the cells of the inner cell mass (ICM) and the embryonic 
stem cells retain the capacity to build up all three primary germ layers, as well as the primordial 
germ cells, and are pluripotent. Stem cells in the fetal tissues exist during fetal development and 
some stem cells are retained until adult age. In adult tissues, multipotent stem and progenitor cells 
exist in tissues and organs to replace lost or injured cells. Figure downloaded from  
http://synentec.com/imagetypes/content_image_full/stem_cell_development_function_3.png 
 
Fig 4. Light microscopic images showing adipose stem cells (AT-MSCs) proliferation at day 1 (A), 
2 (B) and 4 (C) post isolation. Fluorescence microscope image of live/dead staining of ASCs and 
biomaterial, with live cells (green) and dead cells (red) depicting cell adhesion to the biomaterial 
and cell viability (D) and (E). (Reprint from Mesimäki et al 2009 granted by Elsevier)  
 
Fig 5. Confirming the multipotent nature of AT-MSCs. Alkaline phosphatase staining on osteogenic 
differentiation cultures of AT-MSCs and biomaterial, control culture (A) and differentiation culture 
(B). Oil red O staining confirming adipose differentiation of AT-MSCs cultured in monolayer (C). 
Alcian blue staining confirming chondrogenic differentiation of AT-MSCs cultured in micro mass 
culture format (D).    (Reprint from Mesimäki et al. 2009 granted by Elsevier)  
 
Fig 6. Preoperative clinical status 28 months after removal of keratocyst by hemimaxillectomy (A). 
Final result 1 year after bone and soft tissue reconstruction, with temporary dental implant 
rehabilitation (B). (Reprint from Mesimäki et al 2009 granted by Elsevier) 
 
Fig 7. Second and third operation. (A) The titanium cage filled with ß-TCP 
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and adipose stem cells, before insertion in the prepared rectus abdominis muscle pouch. (B) The 
bony regenerate in the rectus abdominis muscle. Skeletal scintigraphy was performed to confirm 
bone activity. (C) The rectus abdominis free-flap raised, muscle pouch and titanium cage 
opened. Note bleeding from the bone. The tissue engineered bone was clinically confirmed to be 
rigid. (D) Histological section of the biopsy from the tissue-engineered bone showing normal 
mature bone structures. (Reprint from Mesimäki et al 2009 granted by Elsevier) 
 
Fig 8. Final reconstruction. A and B. The flap was left to epithelialize and prosthetic rehabilitation 
was carried out with a fixed bridge. C. Part of the titanium cage was removed to enable placement 
of implants. (Courtesy of Dr. Jari Mauno)  
 
Fig 9. In the future, extracellular vesicles (EVs) secreted by stem cells could be used in tissue 
engineering avoiding some adverse effects in the use of stem cells. EVs could be harvested from 
e.g. fat tissue or blood either autologous or allogeneic, and triggered to enhance bone formation is a 
defect site in a similar fashion as MSCs would, thus avoiding potential adverse immune reactions. 
Harnessing the paracrine effects of stem- and progenitor cells without having to administer living, 
replicating, potentially pluripotent cell populations is an advantage in regard to safety, regulation, 
and complexity. 
 
  
 
 
 
 
 
 
 
 
 
